Stephen Basil Thomas - 27 Jun 2025 Form 4 Insider Report for Climb Bio, Inc. (CLYM)

Reporting relationship: Director
Issuer ticker: CLYM
Reported as of: 27 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Jul 2025, 16:32:24 UTC
Prior SEC filing: 05 Jun 2025
Next SEC filing: 11 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Chandra Adams, as Attorney-in-Fact

Key filing fact

Stephen Basil Thomas filed Form 4 for Climb Bio, Inc. (CLYM) on 01 Jul 2025.

Key facts

This page summarizes Stephen Basil Thomas's Form 4 filing for Climb Bio, Inc. (CLYM).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 01 Jul 2025, 16:32.

Change

Previous filing in this sequence was filed on 05 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002027962 Primary reporting owner

Thomas Stephen Basil

Relationship: Director
Address: C/O CLIMB BIO, INC., 20 WILLIAM STREET, SUITE 145, WELLESLEY HILLS
Signature: /s/ Chandra Adams, as Attorney-in-Fact
Signature date: 01 Jul 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CLYM transaction

Common Stock

Options Exercise

Transaction value
Shares: +25,094
Change %: +14%
Price
Shares after: 204,282
Date: 27 Jun 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CLYM transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -25,094
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 27 Jun 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,094
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.

Footnote F2

Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F3

The RSUs were granted on June 27, 2024 and vested as to 50% of the shares on January 1, 2025, vested as to 25% of the shares on March 27, 2025 and vested as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.

SEC remarks

Exhibit Index: 24.1 - Power of Attorney